r.jhannsdttir
TL3 Regular · Parma, IT
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 4 January 2025 · last posted 3d · groups: journal-club
156Posts here
2Topics
0Solutions
986Likes received
710Likes given
27Badges
139Days visited
2.4kPosts read
Stated areas
Recent activity
Full stream-
Programming during a large energy deficit Replied, post #49 · Nutrition & Training › Resistance training · 25 Jul 2026 · 17 likes Programming during a large energy looks different depending on whether you are reading the primary literature or the summaries of it, and the difference is not in our…
-
Why cagrilintide alone is discussed so much less than in combination — does this still… Replied, post #30 · Compounds › Cagrilintide & amylin analogues · 24 Jul 2026 · 14 likes Second this, and I would have said it less carefully.
-
Revisiting: Protein density versus volume when you cannot eat much Replied, post #92 · Nutrition & Training › Protein & intake · 22 Jul 2026 · 4 likes Saving this. It is the version I will quote when the question comes round again.
-
How shortages have affected compounding permissions Replied, post #58 · Access › Shortages · 21 Jul 2026 · 1 like Nothing to add, except that this is the answer I would give if asked.
-
What a certificate commits its issuer to Replied, post #45 · Analytics › COA interpretation · 17 Jul 2026 · 23 likes Answering the question post #41 raises rather than the one it answers. A chromatogram supplied as a small image is legible for peak shape and not for baseline detail.…
-
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #85 · Practice › Storage & stability · 9 Jul 2026 · 18 likes Trying to state the peptide position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
-
Revisiting: What pooling buys you and what it destroys Replied, post #84 · Evidence › Meta-analyses · 9 Jul 2026 · 0 likes Where the pooling buys discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence…
-
Why side effects reset at each escalation and that is not a failure Replied, post #4 · Practice › Side effects · 7 Jul 2026 · 33 likes Worth separating two things that post #2 runs together. Effects that improve with time and effects that improve with dose reduction are different findings. Working out…
-
I have no scientific background — can I still follow the analytics categories? Replied, post #34 · Start Here › Welcome · 6 Jul 2026 · 0 likes The Lounge is a real category rather than a dumping ground. The sourcing rule still applies there, which surprises people, but the register is looser and nobody minds a…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #49 · Analytics › Home & field testing · 3 Jul 2026 · 0 likes Worth separating two things that post #47 runs together. The version of consumer-accessible tests that I was taught turned out to be a teaching simplification. Useful,…
-
Revisiting: Journal club: SURMOUNT-1, read without the press release Replied, post #62 · Evidence › Journal club · 29 Jun 2026 · 13 likes Post #58 put the caveat in the right place and I want to underline it. Distinguishing three things in the SURMOUNT-1 discussion that keep getting used interchangeably:…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #48 · Sourcing › Independent verification · 28 Jun 2026 · 11 likes VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing…
Maintains 4 documents
- STEP 4 — trial digestReview due 29 Apr 2027
- SELECT — trial digestReview due 26 Nov 2026
- SCALE — trial digestReview due 6 May 2027
- Orforglipron phase 2 (obesity) — trial digestReview due 4 Apr 2027